Announcing the new issue of Prime’s managed care report, featuring the latest trends and updates in medical and pharmacy benefits

Prime Therapeutics/Magellan Rx (Prime/MRx) today launched the spring edition of Magellan Rx Report featuring timely topics such as single-treatment gene therapies and value-based contracting to address the dynamic growth trend and cost of gene and cell therapies. The triannual Magellan Rx Report provides an in-depth analysis of trends associated with high-cost, innovative therapies and the latest updates to inform our clients’ coverage and benefit decisions. 

The Magellan Rx Report spring edition includes expert commentary on the following topics: 

• Single-treatment gene therapies and proper management  
• Myasthenia gravis treatment advances and associated payer impact 
• Ophthalmic update on new treatment options and management strategies 
• Tumor biomarkers in breast cancer – ESR1 testing and targeted therapies 
• Product spotlight: Leqembi for Alzheimer’s disease 
• Update on new FDA-approved biosimilars 
• Pipeline drug list update 

Download a copy of the report to go deeper into these timely trends. 

Stay current on ways Prime/MRx is reimagining pharmacy management to provide the same care we would want for our loved ones.